# Quarry Thera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quarry-thera

- Industry: Biotechnology
- Headquarters: New Haven, US
- Total disclosed funding: $32M
- Latest round: Series A (Nov 24, 2025)
- Investors on record: 4

## About

Founded in 2025 by Mikael Dolsten, and based in Connecticut, US, Quarry Thera is a biotechnology company that provides proximity-induced therapeutics using molecular glue technology. In November 2025, Quarry Thera raised USD 32 million in series A funding from new investors Canaan Partners, F-Prime Capital, Lilly Ventures, and Yosemite Management.
Quarry Thera is a biotechnology company focused on developing proximity-induced therapeutics using molecular glue technology. It utilizes proprietary DNA-encoded libraries, structure-guided drug design, and advanced medicinal chemistry to address proteins that were previously considered untreatable. The company aims to address limitations of current therapies by creating small-molecule drugs that induce proximity between proteins to modulate their function.

## Funding rounds

- Series A, Nov 24, 2025, $32M — Canaan Partners, Lilly Ventures, F-Prime Capital, Yosemite Management

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Yosemite Management (https://capitalatlas.ai/funds/yosemite-management) — Series A